Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)

BACKGROUND: Plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII; VONCENTO(®), CSL Behring) is a high-concentration, low-volume, high-purity concentrate, with a high level of VWF high-molecular-weight multimers and a VWF/FVIII ratio of ~2.4:1. METHODS: This study (NCT01229007) investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Djambas Khayat, Claudia, Iosava, Genadi, Romashevskaya, Irina, Stasyshyn, Oleksandra, Lopez, Marta Julia, Pompa, Maria Teresa, Rogosch, Tobias, Seifert, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232873/
https://www.ncbi.nlm.nih.gov/pubmed/34188580
http://dx.doi.org/10.2147/JBM.S299130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232873/
https://www.ncbi.nlm.nih.gov/pubmed/34188580
http://dx.doi.org/10.2147/JBM.S299130

Ejemplares similares